Drug profile · INN
captopril
CAPOTEN
captopril (CAPOTEN) is a angiotensin-converting enzyme inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — captopril
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
captopril (CAPOTEN) is a angiotensin-converting enzyme inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Angiotensin-converting enzyme inhibitor
Primary target: Angiotensin-converting enzyme
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is captopril?
captopril (CAPOTEN) is a angiotensin-converting enzyme inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for captopril?
CAPOTEN is a marketed brand name for captopril. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of captopril?
captopril has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.